You are here: Industry Insights > ADC

News List

ADC Bio secures additional equity round investment cphi-online
November 27, 2018
ADC Biotechnology (ADC Bio) has secured additional funding of £2.5 million from existing investors and company management. The finance will be deployed to ensure the achievement of specific
ADC Bio Secures £2.5M Investment contractpharma
November 19, 2018
ADC Biotechnology(ADC Bio), announces that it has secured additional funding of 2.5 million from existing investors and
ADC Market to Grow to $4B contractpharma
October 10, 2018
A new analysis in the CPhI Annual Report estimates the increase in growth by 2023
ADC Therapeutics brings in $200 million of financing pharmafile
October 25, 2017
ADC Therapeutics has won some serious financial support after its latest financing round managed to net the company $200 million.
Glythera and IONTAS to collaborate for development of multiple antibodies for next-generation Antibo pharmaasia
September 26, 2017
This collaboration will capitalise on the Glythera ADC development expertise and Iontas' experience in antibody discovery services for optimal effect.
UK firms link to develop ADCs for cancer pharmatimes
September 21, 2017
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Astellas announces wind-down of Agensys research operations biospectrumasia
July 28, 2017
Astellas plans to complete the wind-down of Agensys research operations in the first quarter of calendar 2018.
Morphotek Launches ADC Services Business contractpharma
April 05, 2017
Aligns antibody engineering and clinical development assets into a client-focused ADC business
NBE-Therapeutics Expands Board of Directors by the Appointment of Hans-Peter Gerber b3cnewswire
April 05, 2017
NBE Therapeutics AG, a biopharmaceutical company developing next generation ADC products based on its Transpo-mAb™ antibody platform...
Seattle Genetics gains rights to Immunomedics' experimental cancer drug sacituzumab govitecan firstwordpharma
February 13, 2017
Seattle Genetics agreed to license exclusive global rights to develop, manufacture and commercialise Immunomedics' experimental cancer drug sacituzumab govitecan under a deal potentially worth around $2 billion, the companies announced Friday.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page